DaVita (DVA)
(Delayed Data from NYSE)
$149.96 USD
+1.08 (0.73%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $149.99 +0.03 (0.02%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$149.96 USD
+1.08 (0.73%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $149.99 +0.03 (0.02%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth B Momentum A VGM
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
DVA vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
DaVita HealthCare (DVA) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
DaVita (DVA) Earnings Beat Estimates in Q2, Revenues Miss
by Zacks Equity Research
DaVita's (DVA) dialysis services in the United States were solid in Q2.
DaVita HealthCare (DVA) Beats Q2 Earnings Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 51.16% and -1.13%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
DaVita (DVA) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Solid performance within net dialysis and related lab patient service segment is likely to have contributed to DaVita's (DVA) top line in Q2.
DaVita HealthCare (DVA) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Growth-Focused MedTech Stocks to Buy Amid Coronavirus Crisis
by Sriparna Ghosal
Once the pandemic-led crisis is over, these MedTech growth-focused stocks will flourish on a number of positive developments.
Top Ranked Growth Stocks to Buy for July 9th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, July 9th.
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
3 Affordable MedTech Growth Stocks to Buy Amid Market Unrest
by Debanjana Dey
Here are some MedTech stocks which might be a solid investment option amid the coronavirus-battered market conditions.
New Strong Buy Stocks For July 8th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Is DaVita (DVA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (DVA) Outperforming Other Medical Stocks This Year?
Here's Why You Should Retain DaVita in Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on DaVita (DVA), thanks to solid prospects.
Here's Why You Should Retain VEEVA Systems (VEEV) Stock Now
by Zacks Equity Research
Investor confidence is high in VEEVA Systems (VEEV), thanks to solid prospects.
DVA vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Has DaVita (DVA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (DVA) Outperforming Other Medical Stocks This Year?
Surmodics Gets CE Mark for SurVeil Drug-Coated Balloon
by Zacks Equity Research
Surmodics' (SRDX) receipt of CE Mark for SurVeil DCB should boost the company's Medical Devices segment.
DexCom's (DXCM) G6 CGM System Gets CE Marking in Europe
by Zacks Equity Research
DexCom (DXCM) announces the receipt of CE Marking across Europe for its G6 CGM System.
5 Coronavirus-Proof PEG Picks Suitable for GARP Investors
by Urmimala Biswas
PEG-based investing can be more rewarding with the addition of a few other relevant parameters amid coronavirus-led market rattle.
Is DaVita HealthCare (DVA) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Is DaVita (DVA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (DVA) Outperforming Other Medical Stocks This Year?
Should Value Investors Buy DaVita HealthCare (DVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DVA vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Is DaVita (DVA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (DVA) Outperforming Other Medical Stocks This Year?